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42.7% were female. A 16 item instrument was developed and
reﬁned using cognitive interviews (n = 26). The new instrument is
currently being evaluated for validity and sensitivity. CONCLU-
SIONS: Patient self-management of type 2 diabetes is a crucial
element of successful outcomes in both research studies and
clinical practice settings. The Diabetes Self-Management Proﬁle
will be useful for measuring the impact of different treatment
modalities on patients’ ability to manage the multiple aspects of
their Type 2 diabetes.
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OBJECTIVES: To validate the Human Growth Hormone Pref-
erence and Satisfaction Questionnaire (HGH-PSQ), a new instru-
ment for assessing preference for and satisfaction with HGH
treatment modalities. METHODS: Following IRB approval, the
initial instrument was pilot tested at 4 clinical sites specializing in
pediatric endocrinology. Clinicians, patients, and parents partici-
pated in assessing the properties, overall functionality, and com-
prehension of the instrument. Eligible patients completing the
instrument were children and adolescents 10–18 years old, and
were either new or established users of HGH. Face validity,
statistical validity, internal reliability, domain intercorrelations,
and test-retest reliability were assessed for each domain, as well
as for the entire instrument. RESULTS: Forty-nine patients and
their parents were administered the instrument, with 48 complet-
ing the retest. Following structured feedback and statistical
analysis, the ﬁnal instrument was reduced to 27 items in the
patient version and 30 items in the parent version, covering 5
domains of affect, non-interference, ease of administration/
preparation, pain, and overall satisfaction. Structured develop-
ment of the instrument with input from clinicians,
psychometricians, patients and their families ensured maximum
face validity. Variability and distribution in scores supported
statistical validity of the instrument. Strong internal reliability
was indicated, with Cronbach’s alpha of 0.85 and 0.89 for the
patient and parent versions, respectively. Intercorrelation coefﬁ-
cients for each domain with the overall instrument score demon-
strated convergent and discriminant validity. The instrument also
had good overall test-retest reliability, with correlations of 0.80
for patients and 0.73 for parents, with moderate to good coefﬁ-
cients for the individual domains. CONCLUSIONS: The HGH-
PSQ shows good psychometric properties and appears to be a
valid and reliable instrument to evaluate overall treatment satis-
faction with and patient preference for HGH delivery devices.
Future studies using larger samples of new users with HGH are
warranted to examine the sensitivity of the instrument to detect
differences among treatments.
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OBJECTIVES: Insulin is a potent drug available to manage dia-
betes and avoid serious complications and disease progression.
Unfortunately, psychological insulin resistance (PIR) is not
uncommon and negatively inﬂuences both initiation and com-
pliance with insulin treatment. Thus, understanding etiologies
of PIR is critical to ensure optimal diabetes management.
METHODS: Systematic literature review of peer reviewed jour-
nals using MEDLINE database including all articles (English)
from 1985–2007. The keywords and phrases used for the
search included psychological insulin resistance, type 1/2 dia-
betes, resistance to insulin therapy, insulin side effects/
complications, reluctance to treat, treatment refusal, barriers to
compliance, switching, racial/ethnic/cultural/gender issues/
barriers initiating insulin, patient reluctance, psychological
adjustment, needle/injection anxiety/phobia/fear, psycho-social
aspects, patient perceptions, acceptance/adherence and patient
preference. A total of 106 articles were reviewed. RESULTS:
Multiple etiologies of PIR were identiﬁed including patients’
beliefs and knowledge about diabetes/insulin, negative self per-
ceptions and attitudinal barriers, fear of side effects, complica-
tions from insulin use, social stigma and lifestyle adaptations
required by insulin use. Gender, socio-economics and culture
may modify this impact. Additionally, individual or physician
beliefs that one cannot comply with treatment or cope with
repeated blood tests, fear of hypoglycemia or weight gain and
physicians’ previous experience with insulin may also contrib-
ute to PIR. These etiological inﬂuences, both independently
and in combination, constitute patients’ PIR and may results
in compromised glucose control. CONCLUSIONS: PIR is
complex and multifaceted and plays an important, often
ignored role in diabetes management. This presentation will
review the full scope of PIR etiologies and discuss treatment
implications. Assisting health care professionals to better under-
standing PIR and tailor insulin treatment modalities accord-
ingly (e.g., with modern insulin analogues associated with less
weight gain and less hypoglycemia and/or insulin pen devices),
may greatly reduce patients’ PIR associated with using human-
insulin in vial and syringe.
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OBJECTIVES: Approximately 90% of the diabetes population
has type 2 diabetes, which has been predicted to become the
epidemic of the 21st century. Treatment satisfaction is not only an
important patient-reported outcome (PRO) but also a signiﬁcant
predictor of medication adherence, with implications for the
prevention of long-term complications, e.g. retinopathy, neuropa-
thy, nephropathy. The FDAhasmade recommendations regarding
the development and use of PRO measures. Our aim was to
identify treatment satisfaction questionnaires for use in non-
insulin-treated type 2 diabetes and scrutinize their development
history and psychometric properties. METHODS: We used a
PICO (population, intervention, competitor and outcome) strat-
egy to search Scopus from 2000 to present for relevant articles.
Key search terms included “type 2 diabet*” and “satisfact*”.
Following screening, speciﬁc searches for instrument names and
citation searches were then conducted.RESULTS:A total of 2154
abstracts were screened. Four treatment satisfaction instruments
were identiﬁed as designed for use in non-insulin-treated type 2
diabetes: the Diabetes Treatment Satisfaction Questionnaire
(DTSQ), the Diabetes Medication Satisfaction (Diab-MedSat)
questionnaire, the Diabetes Tablet Treatment Questionnaire
(DTTQ) and the Satisfaction with Oral Anti-Diabetic Agent Scale
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